Doctors Revision

Anti-Tuberculosis and Anti-Leprosy Drugs

Text size
On this page

Overview

The 2HRZE/4HR regimen

Drug-susceptible TB is treated with 2HRZE/4HR: four drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) for 2 months (intensive phase), then isoniazid + rifampicin for 4 months (continuation phase), all dosed daily by weight bands and preferably given as fixed-dose combination tablets.

Figure 1: Timeline of the 2HRZE/4HR tuberculosis regimen showing intensive phase drugs with adult and child doses and the role of each drug
Figure 1: The two phases of TB treatment and what each drug contributes.

Why four drugs? M. tuberculosis mutates to resistance at a fixed, low rate per division. A bacillus resistant to one drug exists in every large population; a bacillus spontaneously resistant to four drugs is vanishingly rare. Combining drugs with different mechanisms therefore protects the regimen — provided adherence is good, because erratic single-drug exposure is how resistance emerges. Each drug also covers a different bacterial subpopulation (figure 1): isoniazid kills rapidly dividing bacilli, pyrazinamide kills acidic semi-dormant bacilli in caseous foci, rifampicin sterilises lesions by killing semi-dormant persisters, and ethambutol protects isoniazid from resistance while smear results are pending. The continuation phase then eliminates the slow-growing persisters that cause relapse if not eradicated.

First-line anti-TB drugs in detail

Scroll the table sideways on a smaller screen.

First-line anti-TB drugs: dose, mechanism, role, adverse effects, monitoring
DrugAdult dosePaediatric doseMechanismRole / bactericidal nicheAdverse effects & monitoringKey interactions / counselling
Isoniazid (H)5 mg/kg once daily (max 300 mg), oral/IM10 mg/kg once daily (max 300 mg); higher mg/kg in young childrenInhibits mycolic-acid synthesis (InhA, katG activation) — bactericidal against dividing bacilliMost potent early bactericide; core of every regimen; also used alone for TB preventive therapy (6–9 months)Hepatotoxicity (transaminitis — check LFTs; stop if jaundice), peripheral neuropathy (pyridoxine/vitamin B6 10 mg daily prevents, especially in pregnancy, diabetes, HIV, malnutrition), CNS effects, hypersensitivityAlcohol ↑ hepatotoxicity; phenytoin, carbamazepine, warfarin levels ↑ (monitor); avoid tyramine-rich food reactions (weak MAO inhibition); orange sweat/tears may stain (with combination products)
Rifampicin (R)10 mg/kg once daily (max 600 mg); <50 kg usually 450 mg15 mg/kg once daily (max 600 mg)Inhibits DNA-dependent RNA polymerase (rpoB) — bactericidal against semi-dormant bacilli; sterilising activityThe sterilising drug that permits the 6-month duration; also leprosy and staphylococcal prosthetic-device infectionOrange discoloration of urine, tears, sweat (harmless — counsel!), hepatotoxicity, flu-like syndrome with intermittent dosing, thrombocytopenia (rare), renal impairment (rare)Potent CYP3A4/P-gp inducer — reduces levels of oral contraceptives (use condoms/implant), antiretrovirals (DTG dose ↑, PIs ↓↓), warfarin, many anticonvulsants, azoles; orange soft contact lenses permanently stained
Pyrazinamide (Z)25 mg/kg once daily (weight bands: 1–1.5–2 g)35 mg/kg once daily (max 2 g)Converted by bacterial pyrazinamidase to pyrazinoic acid; active only in acidic pH — kills bacilli in caseous fociIntensive phase only (2 months); allowed shortening from 12 to 6 monthsHepatotoxicity, hyperuricaemia → gouty arthritis (monitor urate; analgesia), nausea, flushingRenal excretion of urate ↓ (allopurinol interaction); avoid in severe hepatic impairment, acute gout
Ethambutol (E)15–20 mg/kg once daily (max 1.6 g); weight-band tablets20 mg/kg once daily (max 1.2 g)Inhibits arabinosyl transferase — blocks arabinogalactan (cell-wall) synthesis; bacteriostaticProtects companion drugs from resistance during the intensive phase until susceptibility known; children: can be omitted in low-HIV, low-isoniazid-resistance settingsOptic neuritis (red-green colour blindness, reduced acuity — baseline and monthly visual questioning/testing; reversible if caught early), dose-related; peripheral neuropathy; hyperuricaemia (mild)Renal impairment: extend interval to 48 h or reduce dose; ask about vision at every visit
Streptomycin (S)15 mg/kg IM once daily (max 1 g); retreatment regimens only15–20 mg/kg IM once dailyAminoglycoside — binds 30S ribosomeFormerly first line; now reserved (retreatment per national programme, some forms of TB meningitis adjunct)Vestibular/ototoxicity, nephrotoxicity — see aminoglycosides postNever with other ototoxins; pregnancy — avoid (fetal VIII-nerve)

Preventing and managing toxicity

  1. Hepatotoxicity (isoniazid, rifampicin, pyrazinamide — all three): check baseline and monthly symptoms; stop the regimen if ALT/AST ≥3× upper limit with symptoms or jaundice, or ≥5× without. Reintroduce sequentially under specialist guidance once resolved.
  2. Peripheral neuropathy (isoniazid): give pyridoxine 10 mg daily to all patients (routine in most programmes), higher risk in pregnancy, diabetes, HIV, alcohol use, malnutrition.
  3. Optic neuritis (ethambutol): ask about blurred vision and red-green confusion monthly; test acuity/colour vision where possible; stop if optic neuritis develops.
  4. Hyperuricaemia/gout (pyrazinamide, ethambutol): usually asymptomatic; treat gout attacks without stopping TB therapy where possible.
  5. Orange body fluids (rifampicin): reassure — urine, tears, sweat turn orange; harmless and expected; it is not blood in urine.

Second-line and drug-resistant TB

Drug-resistant TB (resistance to isoniazid = Hr-TB; multidrug-resistant, MDR = resistant at least to H and R) requires prolonged regimens built from second-line agents under the national TB programme — never improvised at peripheral level.

Scroll the table sideways on a smaller screen.

Second-line anti-TB agents (programme-guided)
Group / agentMechanism / classKey adverse effectsNote
Fluoroquinolones — levofloxacin, moxifloxacinDNA gyraseTendinopathy, QT prolongation, CNSBackbone of MDR regimens; also Hr-TB
Injectable agents — amikacin, capreomycin, streptomycinAminoglycosides / cyclic peptide (30S)Nephro- and ototoxicity (monitor levels)Largely phased out of shorter regimens; injectable-sparing preferred
LinezolidOxazolidinone (50S)Marrow suppression (thrombocytopenia, anaemia), neuropathy, lactic acidosis; weak MAOIHighly effective vs MDR-TB; monitor FBC weekly early
BedaquilineATP synthase inhibitor (novel)QT prolongation (monitor ECG), hepatotoxicityCore of the 6-month BPaLM regimen (bedaquiline + pretomanid + linezolid + moxifloxacin)
PretomanidNitroimidazole (blocks mycolic-acid synthesis)Hepatotoxicity, peripheral neuropathyBPaLM component
ClofazimineImminophenazine (membrane/ respiratory chain)Skin discoloration (red-black, reversible), GI, QT prolongationAlso a leprosy drug
CycloserineCell-wall (D-alanine analogue)Psychosis, depression, seizures — neuropsychiatricPyridoxine co-prescription; avoid in epilepsy/psychiatric illness
DelamanidNitroimidazoleQT prolongation, GIAlternative in children/special situations

Anti-leprosy drugs and MDT

Leprosy (Mycobacterium leprae) is cured with multidrug therapy (MDT), provided free by WHO. The 2018 WHO guidelines use the same three drugs for all patients — dapsone, rifampicin, clofazimine — for 6 months in paucibacillary (PB) and 12 months in multibacillary (MB) disease. MDT cured millions and broke dapsone monotherapy resistance.

Scroll the table sideways on a smaller screen.

WHO multidrug therapy for leprosy (adult doses; child doses scaled by weight)
DrugAdult dose in MDTChild doseMechanism / roleAdverse effects & counselling
Dapsone (DDS)PB: 100 mg daily, self-administered ×6 months. MB: 100 mg daily ×12 months<5 y: 25 mg/day; 6–14 y: 50–100 mg/daySulphone — PABA antagonist blocking folate synthesis; bacteriostatic; daily backbone of MDTHaemolytic anaemia (dose-related; avoid in G6PD deficiency — screen where possible), agranulocytosis (fever/sore throat — stop, check FBC), methaemoglobinaemia (cyanosis), allergic rash/exfoliative dermatitis (sulphonamide-allergic patients must not receive it); hepatotoxicity (rare)
Rifampicin (R)600 mg once monthly, supervised (450 mg if <35 kg)<5 y: 150–300 mg monthly; 6–14 y: 300–450 mg monthlyRNA-polymerase inhibitor; bactericidal — monthly supervised dose kills a huge fraction of bacilliOrange urine (counsel), flu-like syndrome with monthly dosing, hepatotoxicity; same CYP induction as in TB (shorter relevance on monthly dosing)
Clofazimine (CLF)MB: 50 mg daily self-administered + 300 mg once monthly supervised ×12 months<5 y: 100 mg monthly + 100 mg/week; 6–14 y: 150–200 mg monthly + 50 mg/dayImminophenazine dye; bactericidal slowly; anti-inflammatory — controls type 2 reactions (ENL)Red-black skin discoloration and dryness (reversible months after stopping — counsel, crucial for adherence), GI upset, QT prolongation (rare at MDT doses)
  • Reactions are immunological, not drug toxicity: type 1 (reversal) reactions — neuritis, new skin lesions; treat with prednisolone promptly to prevent permanent nerve damage. Type 2 (ENL, erythema nodosum leprosum) — painful nodules, fever, neuritis; thalidomide (specialist; teratogenic) ± clofazimine/steroids.
  • Single-dose rifampicin post-exposure prophylaxis (SDR-PEP) is recommended for eligible adult contacts of index cases.
  • Monthly supervised doses + daily self-administration: adherence support and reaction surveillance are the clinic pillars.

TB–HIV co-treatment principles

  • Start ART within 2–8 weeks of TB treatment (earlier in profound immunosuppression per guidelines); watch for TB-associated immune reconstitution inflammatory syndrome (IRIS) — paradoxical clinical worsening as immunity recovers.
  • Rifampicin + dolutegravir: rifampicin induces DTG clearance → give dolutegravir 50 mg twice daily during and for 2 weeks after rifampicin.
  • Rifampicin + protease inhibitors (LPV/r, ATV/r): rifampicin lowers PI levels markedly — use rifabutin or programme-approved adjustments instead.
  • Rifampicin reduces oral contraceptive efficacy — counsel alternative methods.
  • Continue cotrimoxazole prophylaxis per HIV guidelines; treat opportunistic infections before/while starting ART.

Clinical scenarios

Scenario 1 — New smear-positive pulmonary TB

A 35-year-old, 60 kg, HIV-negative man has cavitary smear-positive TB confirmed by Xpert (rifampicin-sensitive). You start 2HRZE/4HR with weight-band fixed-dose combinations: isoniazid 300 mg, rifampicin 600 mg, pyrazinamide 1.5 g, ethambutol ~1 g daily; add pyridoxine 10 mg. You counsel on orange urine, the danger of stopping early, and arrange a treatment supporter for DOT. At 2 months he is smear-negative and clinically better — continue isoniazid + rifampicin for 4 more months. At month 3 he reports nausea but no jaundice: check LFTs; if ALT <3× with no symptoms, continue with monitoring.

Scenario 2 — The jaundiced patient on TB therapy

Two months into treatment a patient develops anorexia, vomiting and dark urine with jaundice; ALT 6× upper limit. All three hepatotoxic drugs are stopped. Rule out other causes (viral hepatitis, alcohol, ART). Once LFTs fall, drugs are reintroduced one at a time (usually rifampicin first, then isoniazid ± pyrazinamide under specialist guidance), because abandoning effective TB therapy entirely risks relapse and resistance.

Scenario 3 — Multibacillary leprosy at the clinic

A 40-year-old has multiple asymmetric anaesthetic skin patches and a thickened ulnar nerve — MB leprosy (smear/BI per programme). You start MDT: dapsone 100 mg daily + clofazimine 50 mg daily, plus supervised monthly rifampicin 600 mg + clofazimine 300 mg, for 12 months. You counsel explicitly about the red-black skin discoloration from clofazimine — harmless and reversible — because unexplained, it destroys adherence and fuels stigma. Three weeks later he returns with a painful new patch and wrist drop: a type 1 reversal reaction with neuritis — start prednisolone urgently and refer; protecting nerve function is the treatment goal.

Key points

References

  • WHO Guidelines for Tuberculosis Treatment, drug-susceptible and drug-resistant modules (Library reference.)
  • WHO Guidelines for the Diagnosis, Treatment and Prevention of Leprosy, 2018 (Library reference.)
  • Uganda National Tuberculosis and Leprosy Programme guidelines; Uganda Clinical Guidelines 2023 (Library reference.)
  • Katzung's Basic & Clinical Pharmacology — chemotherapy of tuberculosis chapter (Library reference.)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics (Library reference.)

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and pharmaceutical organisations.

For education only. TB and leprosy treatment must follow national programme protocols (NTLP) and the current Uganda Clinical Guidelines — never improvise regimens in practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top